Circadian-based effects of AcSDKP, with or without rhG-CSF on hematologic toxicity of chemotherapy in mice

European Journal of Haematology

Volumn 60, Issue 3, 1998, Pages 181-188

  Li, Xiao Mei ^a   Soulard, Chantal ^b   Filipski, Elisabeth ^a   De Paillette, Evelyne Deschamps ^c   Lévi, Francis ^a,d  

^a HÔPITAL PAUL BROUSSE   (France)

^b Institut Henri Beaufour   (France)

^c IPSEN   (France)

^d Lab 'Rythmes Biologiques C   (France)

Author keywords

AcSDKP; Arabinosylcytosine; Carboplatin; Chemotherapy; Circadian rhythms; Hemopoiesis

Indexed keywords

CARBOPLATIN; CYTARABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SERASPENIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; COLONY FORMING UNIT GM; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031896974     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01020.x     Document Type: Article

References (39)

1. MOORE MAS. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 1991: 78: 1.
2. HILL ADK, NAAMA, HA, CAIVANO SE, DALY JM. The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications. J Leuk Biol 1995: 58: 634.
3. MOORE JO, DODGE RK, AMREIN PC, et al. Granulocytecolony stimulating factor (Filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood 1997: 89: 780.
4. HORNUNG RL, LONGO DL. Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high dose cyclophosphamide therapy. Blood 1992: 80: 77.
5. MOORE MAS. Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it? Blood 1992: 80: 3.
6. FRINDEL E, GUIGON M. Inhibition of CFU entry into cycle by a bone marrow extract. Exp Hematol 1977: 5: 74.
7. LENFANT M, WDZIECZAK-BAKALA J, GUITTET E, PROME JC, SOTTY D, FRINDEL E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci USA 1989: 86: 779.
8. FRINDEL E, MONPEZAT JP The physiologic role of the endogenous colony forming units-spleen (CFU-S) inhibitor Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP). Leukemia 1989: 3: 753.
9. GUIGON M, BONNET D, LEMOINE F, et al Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Exp Hematol 1990: 18: 1112.
10. JACKSON JD, YAN Y, EWEL C, TALMADGE JE. Activity of Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Exp Hematol 1996: 24: 475.
11. GUIGON M, MARY JY, ENOUF J, FRINDEL E. Protection of mice against lethal doses 1β-D-arabinofuranosylcytosine by pluripotent stem cell inhibitors. Cancer Res 1982: 42: 638.
12. BOGDEN AE, CARDE P, DESCHAMPS DE PAILLETTE E, MOREAU JP, TUBIANA M, FRINDEL E. Amelioration of chemotherapy induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation. Ann NY Acad Sci 1991: 628: 126.
13. AIDOUDI S, GUIGON M, LEBEURIER I, CAEN JP, HAN ZC. In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-fluorouracil. Br J Haematol 1996: 94: 443.
14. WATANABE T, BROWN G, KELSEY LS, et al. In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulating factor, on murine progenitor cells after sublethal irradiation. Exp Hematol 1996: 24: 713.
15. BONNET D, CESAIRE R, LEMOINE F, AOUDJHANE M, NAJMAN A, GUIGON M. The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells. Exp Hematol 1992: 20: 251.
16. BONNET D, LEMOINE FM, KHOURY E, PRADELLES P, NAJMAN A, GUIGON M. Reversible inhibitory effects and absence of toxicity of the tetrapeplide Acetyl-Ser-Asp-Lys-Pro (AcSDKP) in human long-term bone marrow cultures (LTMCs). Exp Hematol 1992: 20: 1165.
17. + subpopulation in response to growth factors. Blood 1993: 82: 3307.
18. LÉVI F. Chronopharmacology of anticancer agents. In: REDFERN PH, LEMMER B, eds. Handbook of Experimental Pharmacology: physiology and pharmacology of biological rhythms, vol. 125. Berlin: Springer-Verlag, 1997: 299.
19. SCHEVING LE, HAUS E, KUHL JFW, PAULY JE, HALBERG F, CARDOSO S. Close reproduction by different laboratories of characteristics of circadian rhythm in 1-β-D-arabinofuranosylcytosin tolerance by mice. Cancer Res 1976: 36: 1133.
20. BOUGHATTAS NA, LÉVI F, HECQUET B, et al. Circadian time dependence of murine tolerance for carboplatin. Toxicol Appl Pharmacol 1988: 96: 233.
21. LIU XH, METZGER G, SFAKSI N, MISSET JL, LÉVI F. Circadian changes in cell cycle progression and Bcl-2 oncoprotein expression in mouse bone marrow. NSF-CNRS Congress of Biological Rhythms: Physiological and Molecular Mechanisms, Lyon, France, 1997: 38(abstr).
22. PERPOINT B, LE BOUSSE-KERDILÈS C, CLAY D, et al. In vitro Chronopharmacology of recombinant mouse IL-3, mouse GM-CSF, and human G-CSF on murine myeloid progenitor cells. Exp Hematol 1995: 23: 362.
23. WOOD PA, HRUSHESKY WLM. Chronopharmacodynamics of hematopoietic growth factors and antitumor cytokines. In: HRUSHESKY WJM, eds. Circadian Cancer Therapy. Boca Raton: CRC Press, 1994: 185.
24. GROGNET M, CARDE R ISNARD F, et al. The negative regulation of hematopoiesis from fundamental aspects to clinical applications. In: GUIGON M, LEMOINE FM, DAINIAK N, SCHECHTER A, NAJMAN A, eds. Seraspenide: a peptide with hematopoietic regulatory activities. Pharmacokinetics in animals and man. Colloque INSERM, vol. 229. Paris: John Libbey Eurotext. 1993: 191.
25. LI XM, EZAN E, BINDOULA G, et al. Chronopharmacologic aspects of continuous AcSDKP infusion in mice. Exp Hematol 1998: in press.
26. NAKAHATA H, OGAWA M. Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotenlial hemopoietic colonies. Proc Natl Acad Sci USA 1982: 79: 3843.
27. VOLKOV L, QUÉRÉ P, COUDERT F, COMTE L, ANTIPOV Y, PRALORAN V. The tetrapeptide AcSDKP, a negative regulator of cell cycle entry, inhibits the proliferation of human and chicken lymphocytes. Cell Immunol 1996: 168: 302.
28. MASSÉ A, RAMIREZ LH, BINDOULA G, et al. The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors. Blood 1998: 91: 1.
29. WATANABE T, KELSEY LS, YAN Y, et al. In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation. Br J Haematol 1996: 94: 619.
30. GUIGON M, FRINDEL E. Inhibition of CFU-S entry into cell cycle after irradiation and drug treatment. Biomedicine 1978: 29: 176.
31. DUHRSEN U, VILLEVAL JL, BOYD J, et al Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988: 72: 2074.
32. CASHMAN JD, EAVES AC, EAVES JC. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in the long-term culture: evidence for an indirect mechanism. Blood 1994: 84: 1534.
33. LENFANT M, ITOH K, SAKODA H, et al. Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line M-S-1-T by a tetrapeptide Acelyl-N-Ser-Asp-Lys-Pro. Exp Hematol 1989: 17: 898.
34. AIZAWA S, TOYAMA K, MORI KJ, FRINDEL E. Biological activities of tetrapeptide AcSDKP on hemopoietic cell binding to the stromal cell in vitro. Exp Hematol 1992: 20: 896.
35. HONG DS, GRAHAM T, EWEL C, STORB R, DEEG HJ. Inhibition of hematopoicsis in long-term marrow cultures establised on adherent layers from AcSDKP-treated dogs. Exp Hemalol 1995: 23: 639.
36. JACKSON JD, YAN Y, EWEL C, TALMADGE JE. Activity of Acelyl-N-Ser-Asp-Lys-Pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Exp Hematol 1996: 24: 475.
37. + subpopulations in response to growth factors. Blood 1993: 82: 3307.
38. PAUKOVITS WR, LAERUM OD. Isolation and synthesis of a hemoregulatory peptide. Z Naturforsch 1982: 37c: 1297.
39. PAUKOVITS WR, GUIGON M, BINDER KA, HERGL A, LAERUM OD, SCHULTE-HERMANN R. Prevention of hematotoxic side effects of cytostatic drugs in mice by a synthetic hemoregulatory peptide. Cancer Res 1990: 50: 328.